Are Treated Celiac Patients at Risk for Mycotoxins? An Italian Case-Study

• Main Authors: Martina Cirlini, Teresa Mazzeo, Leda Roncoroni, Vincenza Lombardo, Luca Elli, Maria T. Bardella, Carlo Agostoni, Luisa Doneda, Furio Brighenti, Chiara Dall’Asta, Nicoletta Pellegrini
• Format: Article
• Language: English
• Published: MDPI AG 2016-12-01
• Series: Toxins
• Subjects: deoxynivalenol (DON); zearalenone (ZEN); fumonisin B1 (FB1); human urine; celiac patients
• Online Access: http://www.mdpi.com/2072-6651/9/1/11

Urinary biomarkers of mycotoxin exposure were evaluated in a group of celiac patients (n = 55) and in a control group of healthy subjects (n = 50) following their habitual diet. Deoxynivalenol (DON), zearalenone (ZEN), and fumonisin B1 (FB1) were monitored in 105 urinary samples collected from the two groups. Dietary habits were also recorded through compilation of a seven-day weighed dietary diary. Biomarkers of mycotoxin exposure were detected in 21 celiac patients and in 15 control subjects, corresponding to about 34% of total participants. In particular, ZEN was the most detected mycotoxin among all the studied subjects with a total of 19 positive cases. Results did not show a statistically significant difference in mycotoxin exposure between the two groups, and the presence of specific mycotoxins was not related to the intake of any particular food category. Our findings suggest little urgency of specific regulation for gluten free products, although the prevalence of exposure observed in free-living diets of both celiac and healthy subjects underlines the need of a constant surveillance on mycotoxins occurrence at large.